Unlike other GHRPs, Ipamorelin does not affect the release of cortisol, acetylcholine, prolactin, or aldosterone, thus minimizing the adverse side effects of other growth hormone therapies, such as increased hunger
Love the product My energy is increased, with suppression of appetite
When Providers Choose Compounded GLP-1 Therapy Supply chain shortages and prohibitive pricing of commercial GLP-1 medications frequently interrupt patient care
Supports structured energy intake reduction research: By activating satiety circuits and slowing digestion, Cagrilintide reduces caloric intake in controlled experimental settings
Sources: BPC 157 has garnered attention for its potential benefits, particularly in tissue and wound healing